Powered by

Oxurion and Beta Therapeutics enter into strategic research collaboration for development of new heparanase inhibitors to treat retinal disorders

Nov 06, 2018 - Global Banking News

Biopharmaceutical company Oxurion NV (Euronext Brussels: OXUR), a developer of new treatments to preserve vision in patients with diseases affecting the back of the eye, revealed on Monday that it entered into a strategic research collaboration with Beta Therapeutics Pty Ltd (Canberra, Australia) to develop new heparanase inhibitors for the treatment of retinal disorders with the highest unmet medical needs such as dry age-related macular degeneration.

According to the terms of the agreeme...